Get started
Author

Agnes Elekes

Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors
2014 · Johanna C. Bendell, David S. Hong, et al. · Cancer Chemotherapy and Pharmacology · 116
Phase 2 placebo-controlled, double-blind trial of dasatinib added to gemcitabine for patients with locally-advanced pancreatic cancer
2016 · T.R.J. Evans, E. Van Cutsem, et al. · Annals of Oncology · 68
PDF
A First-in-Human Phase I Study of OPB-111077, a Small-Molecule STAT3 and Oxidative Phosphorylation Inhibitor, in Patients with Advanced Cancers
2018 · Anthony Tolcher, Keith Flaherty, et al. · The Oncologist · 57
PDF
Safety and Efficacy of Targeted-Dose Busulfan and Bortezomib as a Conditioning Regimen for Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Blood Progenitor Cell Transplantation
2014 · César O. Freytes, Juan J. Toro, et al. · Transplantation and Cellular Therapy · 6
PDF
Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for Lymphoma
2014 · Marcelo C. Pasquini, Jennifer Le Rademacher, et al. · Transplantation and Cellular Therapy · 5
PDF
Pharmacokinetic-Directed Dose Adjustment Is Essential for Intravenous Busulfan Exposure Optimization: Findings From a Multi-Center Phase II Study of Autologous Hematopoietic Stem Cell Transplantation for Lymphoma in North America
2013 · Michael Lill, Luciano J. Costa, et al. · Transplantation and Cellular Therapy · 5
PDF
Abstract B56: A phase 1, open-label, dose escalation, nonrandomized study to assess the maximum tolerated dose, dose limiting toxicity, and pharmacokinetics of OPB-31121 in subjects with advanced solid tumors.
2011 · Razelle Kurzrock, Aung Naing, et al. · Molecular Cancer Therapeutics · 2
Safety of PK-Guided IV Bu Cy VP-16 Preparative Regimen Prior to Autologous Hematopoietic Stem Cell Transplantation for Lymphoma: Findings From a Multi-Center Phase II Study in North America
2012 · Luciano J Costa, Michael Lill, et al. · Blood · 1
Final Report of Safety and Efficacy From a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation.
2012 · Edward A. Stadtmauer, Voravit Ratanatharathorn, et al. · Blood · 1
Pharmacokinetics and Safety of Once-Daily Intravenous Busulfan with Bortezomib in Patients with Relapsed Multiple Myeloma Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation
2012 · C.O. Freytes, J.J. Toro, et al. · Transplantation and Cellular Therapy · 1
PDF
Abstract B118: A phase 1, open-label multiple dose escalation trial to determine safety and tolerability of once daily OPB-111077 in subjects with advanced cancer
2015 · Gregory Cote, Kyriakos Papadopoulos, et al. · Molecular Cancer Therapeutics
Efficacy Of a Pharmacokinetics-Directed IV Busulfan (Bu), Plus Cyclophosphamide (Cy) and Etoposide (E) Preparative Regimen With Autologous Hematopoietic Stem Cell Transplantation For Lymphoma: Final Report Of a Multi-Center Phase 2 Study In North America
2013 · Christopher R. Flowers, Michael Lill, et al. · Blood
Safety and Efficacy From Intravenous Busulfan with PK-Directed Dosed Adjustment and Bortezomib Conditioning Regimen in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation
2013 · Voravit Ratanatharathorn, Edward A. Stadtmauer, et al. · Transplantation and Cellular Therapy
Dose Precision Using a Pretransplant Test PK of Intravenous Busulfan Prior to BuCyVP-16 Preparative Regimen in Lymphoma
2012 · M. Lill, S. Lim, et al. · Transplantation and Cellular Therapy
PDF
Pharmacokinetics and Safety of a Novel Conditioning Regimen, Individualized Once-Daily Intravenous Busulfan with Bortezomib, in Relapsed Multiple Myeloma Patients Undergoing a Second Autologous Hematopoietic Stem Cell Transplantation
2011 · Cesar O. Freytes, Juan J. Toro, et al. · Blood
Works count: 15
Citation count: 262
H-index: 5
I10-index: 3
Year
Topic
Type